M&A Deal Summary

ArchiMed Acquires Corealis Pharma

On May 24, 2022, private equity firm ArchiMed acquired life science company Corealis Pharma

Acquisition Highlights
  • This is ArchiMed’s 11th transaction in the Life Science sector.
  • This is ArchiMed’s 2nd transaction in Canada.
  • This is ArchiMed’s 1st transaction in Quebec.

M&A Deal Summary
Date 2022-05-24
Target Corealis Pharma
Sector Life Science
Buyer(s) ArchiMed
Deal Type Recapitalization

Target

Corealis Pharma

Laval, Quebec, Canada
Corealis Pharma is a provider of formulation development and clinical supply manufacturing. The company offers a spectrum of R&D services focused exclusively on pharmaceutical oral solid dosage forms (i.e. tablets, capsules, and granules) and Current Good Manufacturing Practices (cGMP) services for phase I, II and to a lesser extent, early phase III studies. COREALIS has R&D laboratories, cGMP laboratories, and phase I, II, and early phase III clinical trial manufacturing packaging suits. Corealis Pharma was founded in 2005 and is based in Laval, Quebec.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ArchiMed

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2014
PE ASSETS 8.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.

DEAL STATS #
Overall 29 of 36
Sector (Life Science) 11 of 13
Type (Recapitalization) 1 of 1
State (Quebec) 1 of 1
Country (Canada) 2 of 2
Year (2022) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-09 Eurolyser

Salzburg, Austria

Eurolyser designs and engineers patented point-of-care testing equipment and kits, diagnosing a wide range of conditions in animals and humans. Point-of-care testing is done at the time of consultation, leading to the immediate availability of results and more timely, informed decisions concerning treatment. Eurolyser was founded in 2005 and is headquartered in Salzburg, Austria.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-07-12 Title21

Phoenix, Arizona, United States

Title21 is a provider of paperless electronic services to cell & gene therapy labs. Title21’s clients include globally preeminent hospital and research institutions, including the Mayo Clinic, Memorial Sloan Kettering Cancer Center, Stanford University, Kaiser Permanente, and the University of Pennsylvania Health System. The fast-growing cell & gene therapy industry is transforming the treatment of life-threatening conditions including genetic disorders like spinal muscular atrophy, and diseases caused by vital infection, including COVID-19. Title21 was formed in 2001 and is based in Pleasanton, California.

Buy -
Mergr

Product

Company

Legal